| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular … C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ... The Lancet Oncology 16 (13), 1306-1315, 2015 | 1220 | 2015 |
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... New England Journal of Medicine 371 (17), 1609-1618, 2014 | 1191 | 2014 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1163 | 2015 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 724 | 2009 |
| Primary tumor location as a prognostic factor in metastatic colorectal cancer F Loupakis, D Yang, L Yau, S Feng, C Cremolini, W Zhang, MKH Maus, ... Journal of the National Cancer Institute 107 (3), dju427, 2015 | 556 | 2015 |
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... Journal of clinical oncology 27 (16), 2622-2629, 2009 | 513 | 2009 |
| Quantitative evidence for early metastatic seeding in colorectal cancer Z Hu, J Ding, Z Ma, R Sun, JA Seoane, J Scott Shaffer, CJ Suarez, ... Nature genetics 51 (7), 1113-1122, 2019 | 417 | 2019 |
| Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical … C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ... JAMA oncology 5 (3), 343-350, 2019 | 411 | 2019 |
| Treatment of metastatic colorectal cancer: ASCO guideline VK Morris, EB Kennedy, NN Baxter, AB Benson III, A Cercek, M Cho, ... Journal of Clinical Oncology 41 (3), 678-700, 2023 | 337 | 2023 |
| Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial G Masi, F Loupakis, L Salvatore, L Fornaro, C Cremolini, S Cupini, ... The lancet oncology 11 (9), 845-852, 2010 | 314 | 2010 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 306 | 2020 |
| ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ... Journal of the National Cancer Institute 109 (12), djx089, 2017 | 253 | 2017 |
| FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ... European journal of cancer 50 (1), 57-63, 2014 | 250 | 2014 |
| Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer GW Prager, J Taieb, M Fakih, F Ciardiello, E Van Cutsem, E Elez, ... New England Journal of Medicine 388 (18), 1657-1667, 2023 | 239 | 2023 |
| Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis G Masi, E Vasile, F Loupakis, S Cupini, L Fornaro, G Baldi, L Salvatore, ... Journal of the National Cancer Institute 103 (1), 21-30, 2011 | 238 | 2011 |
| The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first … G Fucà, V Guarini, C Antoniotti, F Morano, R Moretto, S Corallo, ... British journal of cancer 123 (3), 403-409, 2020 | 236 | 2020 |
| Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer C Cremolini, C Antoniotti, A Stein, J Bendell, T Gruenberger, D Rossini, ... Journal of Clinical Oncology 38 (28), 3314-3324, 2020 | 221 | 2020 |
| Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective M Lambertini, A Toss, A Passaro, C Criscitiello, C Cremolini, C Cardone, ... ESMO open 5 (2), e000759, 2020 | 216 | 2020 |
| Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini, L Fornaro, ... Annals of Oncology 26 (4), 724-730, 2015 | 209 | 2015 |
| BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ... Annals of oncology 26 (10), 2092-2097, 2015 | 203 | 2015 |
Lisa SalvatoreFondazione Policlinico Universitario Agostino Gemelli IRCCS確認したメール アドレス: policlinicogemelli.it